Mather Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Mather Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-132	Closed	-$4.15K	–	2266
2026 Q2	$4.15K	Hold	132	–	–	﹤0.01%	1648
2026 Q1	$3.27K	Buy	+132	New	+$3.14K	﹤0.01%	1637
2025 Q4	–	Sell	-132	Closed	-$2.6K	–	851
2025 Q3	$2.6K	Buy	+132	New	+$2.72K	﹤0.01%	1501
2025 Q2	–	Sell	-132	Closed	-$3.2K	–	841
2025 Q1	$3.2K	Hold	132	–	–	﹤0.01%	1487
2024 Q4	$2.76K	Hold	132	–	–	﹤0.01%	1485
2024 Q3	$2.62K	Sell	132 -333	-72%	-$6.17K	﹤0.01%	1426
2024 Q2	$7.41K	Buy	+465	New	+$7.24K	﹤0.01%	1525

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Mather Group's CPRX Position: Q3 2026 in Review

Mather Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 132 shares — an estimated $4.15K sold.

Mather Group first reported a position in CPRX in Q2 2024 and held it in 7 quarters. The position peaked at $7.41K in Q2 2024. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Mather Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Mather Group sold 132 Catalyst Pharmaceutical shares in Q3 2026, an estimated $4.15K.
Mather Group first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 7 quarters.
Mather Group's Catalyst Pharmaceutical position peaked at $7.41K in Q2 2024.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.